Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.
Rydex Health Care H RYHAX
- NAV / 1-Day Return 37.16 / +0.38 %
- Total Assets 26.8 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.650%
- Distribution Fee Level High
- Share Class Type No Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 116%
USD | NAV as of Oct 05, 2024 | 1-Day Return as of Oct 05, 2024, 12:57 AM GMT+0
Morningstar’s Analysis RYHAX
Will RYHAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 26.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 4.27 | 1.3 Mil | Healthcare |
UnitedHealth Group Inc | 3.67 | 1.1 Mil | Healthcare |
Johnson & Johnson | 3.05 | 955,851 | Healthcare |
AbbVie Inc | 2.89 | 903,222 | Healthcare |
Merck & Co Inc | 2.38 | 743,866 | Healthcare |
Thermo Fisher Scientific Inc | 2.28 | 713,481 | Healthcare |
Abbott Laboratories | 2.10 | 655,720 | Healthcare |
Intuitive Surgical Inc | 2.04 | 636,971 | Healthcare |
Amgen Inc | 2.03 | 636,614 | Healthcare |
Danaher Corp | 2.02 | 630,724 | Healthcare |